US Food and Drug Administration Commissioner Scott Gottlieb has welcomed the signing of new legislation that empowers agencies to take a range of actions to tackle the ongoing epidemic of opioid abuse in the country.
Leveraging new authorities granted under the so-called SUPPORT Act, Dr Gottlieb said the FDA would take immediate steps to reduce the scope of the crisis.
As well as acting to prevent the importation of illegal opioids, the agency would advance innovation in pain medicines that don’t have the same risks as opioids, and develop better treatments for those with opioid use disorder, he said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze